Alpha Teknova, Inc. ( (TKNO) ) has released its Q3 earnings. Here is a breakdown of the information Alpha Teknova, Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Alpha Teknova, Inc., a key player in the life sciences sector, specializes in producing critical reagents essential for the development of novel therapies, vaccines, and molecular diagnostics. The company, headquartered in Hollister, California, is known for its customizable solutions and rapid turnaround times, supporting advancements in molecular diagnostics and synthetic biology.
In its third-quarter 2025 financial results, Teknova reported a total revenue of $10.5 million, marking a 9% increase from the previous year. This growth represents the company’s fifth consecutive quarter of year-over-year revenue increases, despite challenging market conditions for small- to mid-size biotech firms.
Key financial highlights include a significant improvement in gross profit to $3.2 million from $0.1 million the previous year, driven by higher revenue and the absence of non-recurring charges. The Lab Essentials segment saw a 16% revenue increase, offsetting a 13% decline in Clinical Solutions sales. Teknova’s net loss narrowed to $4.3 million, with an improved Adjusted EBITDA of negative $1.6 million compared to negative $5.0 million in 2024.
Looking ahead, Teknova reaffirms its 2025 revenue guidance of $39-42 million and anticipates a Free Cash Outflow of less than $12 million for the year. The company remains optimistic about its long-term growth prospects, supported by its expanding customer base and diverse product offerings.